Patients on benralizumab, dupilumab, or mepolizumab have lower post-vaccination SARS-CoV-2 immunity

Published on
Journal: The Journal of Allergy and Clinical Immunology
[저자] Martin C. Runnstrom, Pedro A. Lamothe, Caterina E. Faliti, Narayanaiah Cheedarla, Alberto Moreno, Mehul S. Suthar, Rishika Nahata, Mayuran Ravindran, Natalie S. Haddad, Andrea Morrison-Porter, Hannah Quehl, Richard P. Ramonell, Matthew Woodruff, Fabliha Anam, Rebeca Zhang, Colin Swenson, Carmen Polito, Wendy Neveu, Rahulkumar Patel, Natalia Smirnova, Caroline Kim, Ian Hentenaar, Shuya Kyu, Sabeena Usman, Thuy Ngo, Zhenxing Guo, Hao Wu, John L. Daiss, Jiwon Park, Kelly E Manning, Bursha Wali, Madison L. Ellis, Sunita Sharma, Fernando Holguin, Suneethamma Cheedarla, Andrew S. Neish, John D. Roback, Ignacio Sanz, F. Eun-Hyung Lee
[Category] update2024,
PMC URL    Pubmed URL    DOI URL    [DOI] 10.1016/j.jaci.2024.03.029    
[Article Type] Article
[Source] PMC

Capsule Summary In a prospective observational study, patients with asthma or atopic dermatitis treated with benralizumab, dupilumab, or mepolizumab exhibited lower post-vaccination SARS-CoV-2 antibody levels, neutralization activity, and Spike-specific lymphocyte memory responses than subjects not on biologics.

All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, memory B cells, mRNA vaccines, memory T cells, Antibody neutralization, Dupilumab, benralizumab, mepolizumab, Asthma biologics,